Thank you for subscribing!
Finfeed Archived Mar 26, 2021
Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.
Finfeed Archived Mar 23, 2021
Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.
Finfeed Archived Mar 17, 2021
Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.
Finfeed Archived Mar 09, 2021
Neurotech International Limited (ASX: NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.
Get expert stock analysis direct in your inbox
Finfeed Archived Feb 15, 2021
Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.
Next Investors Jan 19, 2021
Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.
Catalyst Hunter Archived Dec 16, 2020
Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.
Finfeed Archived Dec 11, 2020
Creso Pharma Limited (ASX:CPH, FRA:1X8) has today announced obtainment of an exclusive Heads of Agreement with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd.
Finfeed Archived Sep 10, 2020
The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).
Join Our Mailing List
